The FDA issued a safety announcement regarding the use of erythropoiesis-stimulating agents (ESAs) in 2010 with the recommendation that:
A) ESAs no longer be prescribed to patients with chronic renal failure
B) The risk of tumor development be explained to cancer patients on ESA therapy
C) Patients should no longer receive ESA therapy to prepare for allogenic transfusions
D) ESAs be prescribed only to patients younger than age 60 years
Correct Answer:
Verified
Q6: The routine monitoring recommended for low molecular
Q7: Patients who are being treated with epoetin
Q8: The safest drug to use to treat
Q9: When patients are started on darbepoetin alfa
Q10: Cecil and his wife are traveling to
Q12: Jim is having a hip replacement surgery
Q13: Kenneth is taking warfarin and is asking
Q14: Robert, age 51 years, has been told
Q15: Patient education when prescribing clopidogrel includes:
A) Do
Q16: Patients receiving heparin therapy require monitoring of:
A)
Unlock this Answer For Free Now!
View this answer and more for free by performing one of the following actions
Scan the QR code to install the App and get 2 free unlocks
Unlock quizzes for free by uploading documents